Article

Ophthalmic suspension drug earns approvable letter from FDA

The FDA issued an approvable letter to Bausch & Lomb in response to the new drug application the company filed in 2003 for its loteprednol etabonate and tobramycin ophthalmic suspension drug (Zylet).

The FDA issued an approvable letter to Bausch & Lomb in response to the new drug application the company filed in 2003 for its loteprednol etabonate and tobramycin ophthalmic suspension drug (Zylet).

Bausch & Lomb indicated that it still aims for approval of the ophthalmic suspension drug during the second half of this year.

The combination therapy is aimed at treating patients with steroid-responsive inflammatory ocular conditions who have or are at risk of developing superficial bacterial ocular infections.

Bausch & Lomb in 2001 acquired the rights to the loteprednol etabonate ophthalmic business of its former marketing partner, Pharmos Corp.

Bausch & Lomb will pay Pharmos a milestone payment to market the product upon its approval.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.